Stanford University
257 Campus Drive
Hagey Laboratory GK200
Stanford
California
94305-5826
United States
36 articles about Stanford University
-
Epic Bio aims to transform genetic medicine by developing a new class of drugs that target the epigenome to alter gene expression.
-
For the exercise-phobic, a pill that would create the benefits of exercise without the work has been a pipe dream. Today, such a pill – actually, an “anti-hunger molecule” – is a bit closer to reality.
-
In a study conducted by researchers at Stanford University, three pediatric patients with a rare genetic disease that often results in kidney failure received kidney transplants.
-
Resolve Biosciences Sets New Standard for Single-Cell Spatial Analysis with Launch of Fully Automated Molecular Cartography™ Workflow
6/7/2022
Pioneering scientists at VIB, the University of Copenhagen, DKFZ, and Stanford University are the first to deploy systems that deliver highest-resolution view of subcellular gene expression activity.
-
How much could a human genome cost? The answer is $100, according to newly launched biotech company Ultima Genomics, which received $600 million in backing.
-
Pancreatic transplants are difficult to pull off for Type 1 diabetes, but new technology may make it possible, and infusions of spinal fluid from young mice to older ones reportedly reverses memory loss.
-
New research from the Allen Institute for Immunology in Seattle has identified inflammatory proteins as a potential driver of the long COVID.
-
Bryostatin-1 increases antigen expression on the surface of cancer cells, enabling them to be seen and killed by IO agents.
-
Turn Bio’s platform is based on using mRNA technology to develop novel medicines to combat age-related diseases.
-
Some researchers are pointing to the need for an intranasal approach to vaccination in order to block the viral particles from gaining a foothold in the body at the point of entry – the nose.
-
APOE4 is associated with an increased risk of Alzheimer’s disease. A European consortium coordinated by the University of Geneva believes they have identified at least one mechanism of action.
-
Deepcell, a biotechnology company spun out of Stanford University in 2017, focuses on quantifying and understanding morphology – part of the cell’s phenotype.
-
Researchers from UCLA believe they may have a possible new approach to treating, and potentially eradicating HIV.
-
Aditxt Signs Amendment to Extend Worldwide Licensing Agreement, Granting Exclusivity in all Fields of Use
12/29/2021
Aditxt, Inc. today announced it had signed an amendment to its February 3, 2020, Exclusive License Agreement with Stanford University, extending Aditxt’s exclusive right to license the technology deployed in AditxtScore™ and securing worldwide exclusivity in all fields of use of the licensed technology (the “Technology”).
-
Arc begins its mission with $650 million in donations from donors. This funding will sustain the scientists and their researchers over renewable eight-year terms.
-
Scientists from Stanford University investigated the effectiveness of an oral tablet flu vaccine called VXA-A1.1 by Vaxart, which uses cellular correlates of protection.
-
Research on the ever-evolving SARS-CoV-2 virus continues as scientists scramble to make sense of it and find cures. Here's a look.
-
Students, Venture Capitalists Launch Equity-Free Program To Support Future Biotech Leaders
9/28/2021
Nucleate, the non-profit organization seeking to support future leaders in the life sciences industry, announced its official launch and immediately opened applications to its Activator program. -
Pixium Vision expands collaboration with Stanford University on next generation Prima System implants
9/8/2021
Pixium Vision SA announces expansion of collaboration with the academic partner Stanford University to develop the second generation of implants for its bionic vision Prima System for dry age-related macular degeneration.
-
BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions
7/8/2021
BridgeBio Pharma, Inc. today announced three new academic collaborations with MUSC Foundation for Research Development, Stanford University and the University of Pittsburgh (Pitt) to translate cutting-edge discoveries into potential therapies for patients with genetic diseases and genetically driven cancers.